Results 171 to 180 of about 617 (209)

S2735 Induction of Inflammatory Bowel Disease by Interleukin-17 Inhibitor

American Journal of Gastroenterology, 2022
Jin Tao, Luqman Baloch, Altaf Dawood, Naser Khan   +3 more
openaire   +1 more source

Interleukin-17 (IL-17) inhibitors in the treatment of plaque psoriasis: a review.

Skin therapy letter, 2016
Acting on keratinocytes to produce antimicrobial peptides and chemokines, which in turn attract neutrophils and other inflammatory cells, interleukin-17 (IL-17) is believed to be a potent driver of plaque psoriasis. Its proinflammatory characteristics make IL-17 an attractive therapeutic target for addressing immune dysregulation.
Melinda, Gooderham, Claudia J, Posso-De Los Rios, Gustavo A, Rubio-Gomez, Kim, Papp   +3 more
openaire   +1 more source

Specific Interleukin-1 Inhibitors, Specific Interleukin-6 Inhibitors, and GM-CSF Blockades for COVID-19 (at the Edge of Sepsis): A Systematic Review

Frontiers in Pharmacology, 2022
Miao Li, Qian Yu, Rui Li
exaly  

S112 Unmasking of Crohn’s Disease With Interleukin-17 Inhibitor Therapy

American Journal of Gastroenterology, 2023
Jena Velji-Ibrahim, Kalpit Devani
openaire   +1 more source

Emerging Therapies for Recurrent Pericarditis: Interleukin‐1 inhibitors

Journal of the American Heart Association, 2021
Reza Reyaldeen, , Massimo Imazio
exaly  

Interleukin Inhibitors in Cytokine Release Syndrome and Neurotoxicity Secondary to CAR-T Therapy

Diseases (Basel, Switzerland), 2022
Isabel Trapero
exaly  

Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis

Journal of drugs in dermatology : JDD, 2019
Psoriasis (PsO) is a common, systemic, chronic inflammatory disease characterized by key clinical symptoms, including itching, pain, and scaling, and is associated with substantial physical, psychosocial, and economic health burdens. Currently, there is no cure for PsO; however, the introduction of biologic therapies has revolutionized the clinical ...
Lawrence J., Green, Paul S., Yamauchi, Leon H., Kircik   +2 more
openaire   +1 more source

Interleukin-17 vs. Interleukin-23 Inhibitors in Pustular and Erythrodermic Psoriasis: A Retrospective, Multicentre Cohort Study

Journal of Clinical Medicine, 2023
Silvia Alberti-Violetti, Simone Ribero, Angelo Valerio Marzano   +2 more
exaly  

Rational Design, Synthesis and Evaluation of Oxazolo[4,5‐c]‐quinolinone Analogs as Novel Interleukin‐33 Inhibitors

Chemistry - an Asian Journal, 2021
Kiho Lee, Youngjoo Byun, Young Ho Jeon
exaly  

Aktuelle Daten zu dualem Interleukin-17-Inhibitor

ästhetische dermatologie & kosmetologie, 2023
openaire   +1 more source